A Phase II clinical trial of the AURKA inhibitor alisertib for advanced PCa patients showed significant clinical benefit in a subset of 4 patients that expressed high levels of AURKA, although the study, overall, did not meet its primary endpoint due to drug toxicity and patient heterogeneity (28). The gene discussed is AURKA; the disease is posterior cortical atrophy.